Progress on Developing Endpoints for Registrational Clinical Trials of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections: Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health
Open Access
- 28 June 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 55 (8), 1114-1121
- https://doi.org/10.1093/cid/cis566
Abstract
Efficacy endpoints for previous registrational trials of antimicrobials for acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP) were based on nonstandardized, clinician-based observations and decisions, as well as on patient reports. More quantifiable, reproducible, and externally verifiable endpoints could improve the design of future noninferiority trials. At the request of the Food and Drug Administration, the Foundation for the National Institutes of Health convened a broadly representative scientific project team to evaluate potential endpoints for such registrational trials. Review of historical and modern data led to the conclusion that antimicrobial treatment effects are most apparent early in therapy; later outcomes provide important supportive information. Although evidence is incomplete, early response endpoints can anchor noninferiority hypotheses in ABSSSI and CABP registrational trials, thereby allowing evidence-based drug development to continue. Further research is underway to establish which short- and long-term outcomes are well-defined, reliable, and reflective of how patients feel, function, or survive.Keywords
This publication has 17 references indexed in Scilit:
- Randomized, Double-Blind, Phase II, Multicenter Study Evaluating the Safety/Tolerability and Efficacy of JNJ-Q2, a Novel Fluoroquinolone, Compared with Linezolid for Treatment of Acute Bacterial Skin and Skin Structure InfectionAntimicrobial Agents and Chemotherapy, 2011
- Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired PneumoniaClinical Infectious Diseases, 2010
- Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double‐Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin‐Structure InfectionClinical Infectious Diseases, 2010
- Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumoniaDiagnostic Microbiology and Infectious Disease, 2008
- Effects of Prior Effective Therapy on the Efficacy of Daptomycin and Ceftriaxone for the Treatment of Community‐Acquired PneumoniaClinical Infectious Diseases, 2008
- Increasing the Efficiency of Clinical Trials of Antimicrobials: The Scientific Basis of Substantial Evidence of Effectiveness of DrugsClinical Infectious Diseases, 2007
- Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue InfectionsAntimicrobial Agents and Chemotherapy, 2005
- IMMUNOLOGICAL STUDIES ON PATIENTS WITH PNEUMOCOCCIC PNEUMONIA TREATED WITH SULFAPYRIDINEJCI Insight, 1940
- Sulphanilamide in the Treatment of ErysipelasBMJ, 1937
- Prontosil in ErysipelasBMJ, 1937